Studies have shown that tumor neoantigens can regulate their fate by promoting the interaction between tumor specific CD4 T cells and tumor specific B cells, thereby enhancing the effector function of CD8 T cells to promote anti-tumor immunity (37). The gene discussed is CD8A; the disease is neoplasm.